FAVO Capital Appoints Dr. Wael Barsoum as Independent Director
FAVO Capital (OTC: FAVO), a diversified financial company operating in financial services and real estate, has appointed Dr. Wael Barsoum as an independent director to its board. Dr. Barsoum brings significant executive experience as the former president and CEO of Cleveland Clinic Florida, where he led growth to over 1,000 physicians and 12,000 caregivers.
Currently serving as president and chief transformation officer at Healthcare Outcomes Performance Company (HOPCo), Dr. Barsoum oversees international and U.S. operations. His expertise includes healthcare innovation, governance, and organizational transformation, supported by his roles as professor at Cleveland Clinic Lerner College of Medicine and member of the Florida State Medical Board.
FAVO Capital (OTC: FAVO), una società finanziaria diversificata operante nei servizi finanziari e nel settore immobiliare, ha nominato Dr. Wael Barsoum come membro indipendente del proprio consiglio di amministrazione. Il Dr. Barsoum porta una significativa esperienza esecutiva in quanto ex presidente e CEO della Cleveland Clinic Florida, dove ha guidato la crescita a oltre 1.000 medici e 12.000 caregiver.
Attualmente ricopre il ruolo di presidente e chief transformation officer presso Healthcare Outcomes Performance Company (HOPCo), supervisionando le operazioni internazionali e statunitensi. La sua expertise comprende innovazione nel settore sanitario, governance e trasformazione organizzativa, supportata dai ruoli di professore alla Cleveland Clinic Lerner College of Medicine e membro della Florida State Medical Board.
FAVO Capital (OTC: FAVO), una empresa financiera diversificada que opera en servicios financieros y bienes raíces, ha nombrado al Dr. Wael Barsoum como director independiente de su junta. El Dr. Barsoum aporta una amplia experiencia ejecutiva, habiendo sido presidente y CEO de Cleveland Clinic Florida, donde lideró el crecimiento a más de 1,000 médicos y 12,000 cuidadores.
Actualmente se desempeña como presidente y chief transformation officer en Healthcare Outcomes Performance Company (HOPCo), supervisando las operaciones internacionales y de EE. UU. Su experiencia abarca innovación en salud, gobernanza y transformación organizacional, respaldada por sus roles como profesor en la Cleveland Clinic Lerner College of Medicine y como miembro de la Florida State Medical Board.
FAVO Capital (OTC: FAVO)는 금융 서비스와 부동산 분야에서 활동하는 다각화된 금융 회사로, Dr. Wael Barsoum 박사를 이사회 독립 이사로 임명했습니다. Barsoum 박사는 Cleveland Clinic Florida의 전 회장 겸 CEO로서 1,000명 이상의 의사와 12,000명의 간병인을 이끄는 등 상당한 경영 경험을 제공합니다.
현재 Healthcare Outcomes Performance Company(HOPCo)에서 사장 겸 혁신책임자(CTO)로 재직하며 국제 및 미국 운영을 감독합니다. 그의 전문 분야는 의료 혁신, 거버넌스 및 조직 변혁이며, Cleveland Clinic Lerner College of Medicine의 교수 및 Florida State Medical Board의 구성원으로서의 역할로 뒷받침됩니다.
FAVO Capital (OTC: FAVO), une société financière diversifiée opérant dans les services financiers et l’immobilier, a nommé le Dr Wael Barsoum administrateur indépendant de son conseil. Le Dr Barsoum apporte une expérience exécutive considérable en tant qu’ancien président et PDG de Cleveland Clinic Florida, où il a mené la croissance à plus de 1 000 médecins et 12 000 soignants.
Actuellement président et chief transformation officer chez Healthcare Outcomes Performance Company (HOPCo), il supervise les opérations internationales et américaines. Son expertise couvre l’innovation en soins de santé, la gouvernance et la transformation organisationnelle, soutenue par ses fonctions de professeur à la Cleveland Clinic Lerner College of Medicine et membre du Florida State Medical Board.
FAVO Capital (OTC: FAVO), ein diversifiziertes Finanzunternehmen, das im Bereich Finanzdienstleistungen und Immobilien tätig ist, hat Dr. Wael Barsoum zum unabhängigen Director (Direktor) seines Vorstands ernannt. Dr. Barsoum bringt umfassende Führungserfahrung mit als ehemaliger Präsident und CEO der Cleveland Clinic Florida, wo er das Wachstum auf über 1.000 Ärzte und 12.000 Pflegekräfte vorangetrieben hat.
Derzeit ist er Präsident und Chief Transformation Officer bei Healthcare Outcomes Performance Company (HOPCo) und beaufsichtigt internationale und US-Operationen. Seine Expertise umfasst Gesundheitsinnovation, Governance und organisatorische Transformation, unterstützt durch seine Rollen als Professor an der Cleveland Clinic Lerner College of Medicine und Mitglied des Florida State Medical Board.
فـAVO Capital (التداول: FAVO)، شركة مالية متنوّعة تعمل في الخدمات المالية والعقارات، عينت الدكتور وائل Barsoum كعضو مستقل في مجلس الإدارة. يجلب الدكتور Barsoum خبرة تنفيذية كبيرة بصفته الرئيس والمدير التنفيذي السابق لـ Cleveland Clinic Florida، حيث قاد النمو إلى أكثر من 1,000 طبيب و12,000 مقدم رعاية.
حالياً، يشغل منصب رئيس ورئيس التحول التنفيذي في Healthcare Outcomes Performance Company (HOPCo)، ويشرف على العمليات الدولية والولايات المتحدة. تشمل خبرته الابتكار في الرعاية الصحية والحوكمة والتحول التنظيمي، مدعومةً بأدواره كأستاذ في كلية الطب لدى Cleveland Clinic Lerner وعضو في مجلس الطب بولاية فلوريدا.
FAVO Capital (OTC: FAVO)，是一家在金融服务和房地产领域运营的多元化金融公司，现任命 Wael Barsoum 博士为独立董事。Barsoum 博士在担任 Cleveland Clinic Florida 的前任总裁兼首席执行官期间，带领团队实现增长至超过 1,000 名医生和 12,000 名护理人员，具备丰富的高管经验。
如今，他在 Healthcare Outcomes Performance Company (HOPCo) 担任主席兼首席转型官，负责国际及美国运营的监督。他的专长包括医疗保健创新、治理与组织转型，并且担任 Cleveland Clinic Lerner College of Medicine 的教授及佛罗里达州医师委员会成员等职务来支撑其专业能力。
- Addition of highly experienced healthcare executive with proven track record in organizational growth
- Enhanced board independence and governance oversight
- Strategic expertise in managing complex organizations and transformation
- None.
Brings governance and large-scale operational expertise to strengthen oversight and support FAVO’s growth strategy
FORT LAUDERDALE, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- via IBN – FAVO Capital Inc. (OTC: FAVO), a diversified financial company operating across two core segments — financial services and real estate— today announced the appointment of Dr. Wael Barsoum to its board of directors as an independent director.
Barsoum is a nationally recognized health care executive and former president and CEO of Cleveland Clinic Florida, where he oversaw transformative growth and operational expansion across the region, scaling the enterprise to more than 1,000 physicians and 12,000 caregivers. He presently serves as president and chief transformation officer at Healthcare Outcomes Performance Company (HOPCo), overseeing international and U.S.-based operations, where he has led large-scale partnerships and value-based care strategies across the U.S. In addition to his executive roles, Barsoum has served as the Robert and Suzanne Tomsich Chair in Healthcare Innovation and professor of surgery at the Cleveland Clinic Lerner College of Medicine, underscoring his ongoing leadership in advancing healthcare innovation. He is also appointed by the governor of Florida to serve on the Florida State Medical Board, reflecting his leadership in statewide healthcare governance.
“Wael’s appointment reflects our commitment to building a board with the independence, depth, and experience to guide FAVO’s next chapter,” said Shaun Quin, president of FAVO Capital. “He brings a proven track record of leading complex organizations with discipline and vision — qualities that will serve our company and shareholders well as we continue to build a resilient platform designed for long-term value creation.”
Barsoum has served on numerous boards and advisory committees, contributing expertise in governance, compliance, and organizational transformation. He previously served on the board of directors of the Cleveland Clinic and is a current member of the board of trustees at Case Western Reserve University, where he continues to provide strategic guidance on organizational growth and stakeholder alignment. His leadership has spanned strategy, risk oversight, and transformation at some of the country’s most respected healthcare institutions.
The appointment further underscores FAVO’s focus on strong governance, independent oversight, and disciplined execution as it builds a durable platform designed to deliver resilient returns across cycles.
About FAVO Capital, Inc.
FAVO Capital, Inc. (OTC: FAVO) is a diversified financial company currently operating across two segments: financial services and selective real assets. Through its financial services division, FAVO provides alternative, revenue-based funding solutions to small and mid-sized businesses across the United States. Since its inception, the company has supported more than 10,000 businesses through the purchase of future receipts. Complementing its lending platform, FAVO is also building a portfolio of selective real assets that strengthen its balance sheet and broaden its collateral base. Headquartered in Fort Lauderdale, Florida, with operations in Florida, New York, and the Dominican Republic, FAVO Capital is committed to financial transparency, sustainable growth, and long-term value creation for its shareholders.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the future financial performance of FAVO Capital, Inc. (the “Company”) and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expects," "plans," "anticipates," "intends," "believes," "estimates," "projects," "potential," "continues," or similar terminology. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the website launch, the Company’s upcoming uplisting to Nasdaq, growth strategy, expansion plans, financial performance, and future business prospects.
These forward-looking statements reflect the Company’s current expectations and projections based on information available as of the date of this release and are subject to risks and uncertainties, including but not limited to general economic, financial, and business conditions; the Company’s leadership going forward; changes in market demand; the Company’s ability to successfully execute its strategic initiatives; the Company’s ability to complete complementary acquisitions and dispositions that benefit the Company; the Company’s continued ability to pay operating costs and ability to meet demand for its financial products and services and real estate operations; the Company’s ability to integrate its newly acquired real estate operations with its existing revenue-based funding solutions; competition in the financial services industry and real estate industry; regulatory compliance; and other risks detailed from time to time in the Company’s filings with the OTC Markets, including its most recent Annual Report and subsequent Quarterly Reports.
The Company cautions investors that forward-looking statements are not guarantees of future performance and actual results may differ materially from those projected. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Company Contact:
FAVO Capital, Inc.
4300 N University Drive, D-105
Lauderhill, FL 33351
www.favocapital.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
Email: ir@favocapital.com
FAQ
Who is Dr. Wael Barsoum and what is his role at FAVO Capital (OTC: FAVO)?
What experience does Dr. Barsoum bring to FAVO Capital's board?
What are Dr. Barsoum's current roles outside of FAVO Capital?
How does Dr. Barsoum's appointment align with FAVO Capital's strategy?
